<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35119317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis.</ArticleTitle>
        <Pagination>
          <StartPage>454</StartPage>
          <EndPage>465</EndPage>
          <MedlinePgn>454-465</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2032482</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is an ordinarily occurring autoimmune disease with systemic inflammatory. Targeted drug delivery systems have many successful applications in the treatment of rheumatoid arthritis. In order to develop nanoparticles for targeted delivery of Celastrol (Cel) to rheumatoid arthritis and specific drug release, the dextran sulfate (DS) was modified as the targeting molecular by binding to the scavenger receptor of macrophage. The dextran-sulfate-PVGLIG-celastrol (DS-PVGLIG-Cel), named DPC, amphiphilic polymeric prodrug was synthesized and characterized. The resulting DPC@Cel micelles had the average size of 189.9 nm. Moreover, the micelles had ultrahigh entrapment efficiency (about 44.04%) and zeta potential of -11.91 mV. In the <i>in vitro</i> release study, due to the excessive production of matrix metalloproteinase-2 (MMP-2) at the inflammatory joint, the MMP-2 reactive peptide was used to crack in the inflammatory microenvironment to accelerate the release of Cel. The results have shown that the nanoparticles can effectively deliver Cel to activated macrophages and significantly improve the bioavailability. <i>In vivo</i> experiments showed that DPC@Cel have better anti-rheumatoid arthritis effects and lower systemic toxicity than free Cel. This study provided a new therapeutic strategy for the treatment of RA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Caiwei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Chunjing</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Marine Life Science, Ocean University of China, Qingdao, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yanguo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Huimin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Xiaoya</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Huaying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mu</LastName>
            <ForeName>Xiaofeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guohua</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6725-1128</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Haiyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Daquan</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-6796-0204</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9042-14-2</RegistryNumber>
          <NameOfSubstance UI="D016264">Dextran Sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.24</RegistryNumber>
          <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L8GG98663L</RegistryNumber>
          <NameOfSubstance UI="C050414">celastrol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016264" MajorTopicYN="N">Dextran Sulfate</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MMP-2 response</Keyword>
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">celastrol</Keyword>
        <Keyword MajorTopicYN="N">dextran sulfate</Keyword>
        <Keyword MajorTopicYN="N">targeting drug delivery system</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35119317</ArticleId>
        <ArticleId IdType="pmc">PMC8855847</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2032482</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bao J, Dai SM. (2011). A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatol Int
31:1123–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21365177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boutet MA, Courties G, Nerviani A, et al.  (2021). Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmun Rev
20:102758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33476818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SR, Dai Y, Zhao J, et al.  (2018). A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F. Front Pharmacol
9:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817256</ArticleId>
            <ArticleId IdType="pubmed">29491837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Z, Zhang W, Hou X, et al.  (2019). Synthesis, characterization, and evaluation of redox-sensitive chitosan oligosaccharide nanoparticles coated with phycocyanin for drug delivery. Nanoscale Res Lett
14:389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6925613</ArticleId>
            <ArticleId IdType="pubmed">31865462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cush JJ. (2021). Rheumatoid arthritis: early diagnosis and treatment. Med Clin North Am
105:355–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33589108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang L, Lin H, Wu Z, et al.  (2020). In vitro/vivo evaluation of novel mitochondrial targeting charge-reversal polysaccharide-based antitumor nanoparticle. Carbohydr Polym
234:115930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32070547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannelli G, Erriquez R, Iannone F, et al.  (2004). MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol
22:335–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15144129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashizume M, Mihara M. (2012). Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine
58:424–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22436638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heo R, You DG, Um W, et al.  (2017). Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis. Biomaterials
131:15–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28371624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou X, Lin H, Zhou X, et al.  (2020). Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis. Carbohydr Polym
232:115787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31952595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashyap D, Sharma A, Tuli HS, et al.  (2018). Molecular targets of celastrol in cancer: recent trends and advancements. Crit Rev Oncol Hematol
128:70–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29958633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keewan E, Naser SA. (2020). The role of notch signaling in macrophages during inflammation and infection: implication in rheumatoid arthritis?
Cells
9:111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7016800</ArticleId>
            <ArticleId IdType="pubmed">31906482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim JH, You DG, et al.  (2013). Self-assembled dextran sulphate nanoparticles for targeting rheumatoid arthritis. Chem Commun
49:10349–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23942894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Wang B, Guo C, et al.  (2019). Novel multifunctional triple folic acid, biotin and CD44 targeting pH-sensitive nano-actiniaes for breast cancer combinational therapy. Drug Deliv
26:1002–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6781222</ArticleId>
            <ArticleId IdType="pubmed">31571501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo D, Zuo Z, Zhao H, et al.  (2019). Immunoregulatory effects of Tripterygium wilfordii Hook F and its extracts in clinical practice. Front Med
13:556–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30604167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes IB, Schett G. (2017). Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet
389:2328–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardeshi CV, Belgamwar VS. (2017). Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation. Artif Cells Nanomed Biotechnol
45:635–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27068140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Aletaha D, Barton A, et al.  (2018). Rheumatoid arthritis. Nat Rev Dis Primers
4:18001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29417936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W, Zhang H, Wang H, et al.  (2017). Targeting notch-activated M1 macrophages attenuates joint tissue damage in a mouse model of inflammatory arthritis. J Bone Miner Res
32:1469–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5489377</ArticleId>
            <ArticleId IdType="pubmed">28256007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang M, Cao X, Zhang K, et al.  (2018). Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression. Cell Death Dis
9:601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5964092</ArticleId>
            <ArticleId IdType="pubmed">29789558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tice RRAgurell E, Anderson D, et al.  (2000). Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing, Environ Mol Mutagen
35(3):206–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10737956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao S, Tang Y, Lv Z, et al.  (2019). Nanomedicine – advantages for their use in rheumatoid arthritis theranostics. J Control Release
316:302–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31715278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Wu G, Wei X, et al.  (2013). Celastrol induced DNA damage, cell cycle arrest, and apoptosis in human rheumatoid fibroblast-like synovial cells. Am J Chin Med
41:615–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23711145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue M, McKelvey K, Shen K, et al.  (2014). Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology
53:2270–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24982240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Ding J, Feng X, et al.  (2017). Scavenger receptor-mediated targeted treatment of collagen-induced arthritis by dextran sulfate-methotrexate prodrug. Theranostics
7:97–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5196888</ArticleId>
            <ArticleId IdType="pubmed">28042319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Feng X, Ding J, et al.  (2017). Nanotherapeutics relieve rheumatoid arthritis. J Control Release
252:108–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28257989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu B, Cheng C, Wu Y, et al.  (2020). Interactions of ferritin with scavenger receptor class A members. J Biol Chem
295:15727–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7667961</ArticleId>
            <ArticleId IdType="pubmed">32907880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yucel Falco C, Falkman P, Risbo J, et al.  (2017). Chitosan-dextran sulfate hydrogels as a potential carrier for probiotics. Carbohydr Polym
172:175–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28606523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Lin X, Zheng R, et al.  (2018). Celastrol alleviates airway hyperresponsiveness and inhibits Th17 responses in obese asthmatic mice. Front Pharmacol
9:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5797758</ArticleId>
            <ArticleId IdType="pubmed">29445341</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35119317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis.</ArticleTitle>
        <Pagination>
          <StartPage>454</StartPage>
          <EndPage>465</EndPage>
          <MedlinePgn>454-465</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2032482</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is an ordinarily occurring autoimmune disease with systemic inflammatory. Targeted drug delivery systems have many successful applications in the treatment of rheumatoid arthritis. In order to develop nanoparticles for targeted delivery of Celastrol (Cel) to rheumatoid arthritis and specific drug release, the dextran sulfate (DS) was modified as the targeting molecular by binding to the scavenger receptor of macrophage. The dextran-sulfate-PVGLIG-celastrol (DS-PVGLIG-Cel), named DPC, amphiphilic polymeric prodrug was synthesized and characterized. The resulting DPC@Cel micelles had the average size of 189.9 nm. Moreover, the micelles had ultrahigh entrapment efficiency (about 44.04%) and zeta potential of -11.91 mV. In the <i>in vitro</i> release study, due to the excessive production of matrix metalloproteinase-2 (MMP-2) at the inflammatory joint, the MMP-2 reactive peptide was used to crack in the inflammatory microenvironment to accelerate the release of Cel. The results have shown that the nanoparticles can effectively deliver Cel to activated macrophages and significantly improve the bioavailability. <i>In vivo</i> experiments showed that DPC@Cel have better anti-rheumatoid arthritis effects and lower systemic toxicity than free Cel. This study provided a new therapeutic strategy for the treatment of RA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Caiwei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Chunjing</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Marine Life Science, Ocean University of China, Qingdao, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yanguo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Huimin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Xiaoya</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Huaying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mu</LastName>
            <ForeName>Xiaofeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guohua</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6725-1128</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Haiyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Daquan</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-6796-0204</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9042-14-2</RegistryNumber>
          <NameOfSubstance UI="D016264">Dextran Sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.24</RegistryNumber>
          <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L8GG98663L</RegistryNumber>
          <NameOfSubstance UI="C050414">celastrol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016264" MajorTopicYN="N">Dextran Sulfate</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MMP-2 response</Keyword>
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">celastrol</Keyword>
        <Keyword MajorTopicYN="N">dextran sulfate</Keyword>
        <Keyword MajorTopicYN="N">targeting drug delivery system</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35119317</ArticleId>
        <ArticleId IdType="pmc">PMC8855847</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2032482</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bao J, Dai SM. (2011). A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatol Int
31:1123–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21365177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boutet MA, Courties G, Nerviani A, et al.  (2021). Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmun Rev
20:102758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33476818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SR, Dai Y, Zhao J, et al.  (2018). A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F. Front Pharmacol
9:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817256</ArticleId>
            <ArticleId IdType="pubmed">29491837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Z, Zhang W, Hou X, et al.  (2019). Synthesis, characterization, and evaluation of redox-sensitive chitosan oligosaccharide nanoparticles coated with phycocyanin for drug delivery. Nanoscale Res Lett
14:389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6925613</ArticleId>
            <ArticleId IdType="pubmed">31865462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cush JJ. (2021). Rheumatoid arthritis: early diagnosis and treatment. Med Clin North Am
105:355–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33589108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang L, Lin H, Wu Z, et al.  (2020). In vitro/vivo evaluation of novel mitochondrial targeting charge-reversal polysaccharide-based antitumor nanoparticle. Carbohydr Polym
234:115930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32070547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannelli G, Erriquez R, Iannone F, et al.  (2004). MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol
22:335–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15144129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashizume M, Mihara M. (2012). Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine
58:424–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22436638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heo R, You DG, Um W, et al.  (2017). Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis. Biomaterials
131:15–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28371624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou X, Lin H, Zhou X, et al.  (2020). Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis. Carbohydr Polym
232:115787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31952595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashyap D, Sharma A, Tuli HS, et al.  (2018). Molecular targets of celastrol in cancer: recent trends and advancements. Crit Rev Oncol Hematol
128:70–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29958633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keewan E, Naser SA. (2020). The role of notch signaling in macrophages during inflammation and infection: implication in rheumatoid arthritis?
Cells
9:111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7016800</ArticleId>
            <ArticleId IdType="pubmed">31906482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim JH, You DG, et al.  (2013). Self-assembled dextran sulphate nanoparticles for targeting rheumatoid arthritis. Chem Commun
49:10349–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23942894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Wang B, Guo C, et al.  (2019). Novel multifunctional triple folic acid, biotin and CD44 targeting pH-sensitive nano-actiniaes for breast cancer combinational therapy. Drug Deliv
26:1002–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6781222</ArticleId>
            <ArticleId IdType="pubmed">31571501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo D, Zuo Z, Zhao H, et al.  (2019). Immunoregulatory effects of Tripterygium wilfordii Hook F and its extracts in clinical practice. Front Med
13:556–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30604167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes IB, Schett G. (2017). Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet
389:2328–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardeshi CV, Belgamwar VS. (2017). Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation. Artif Cells Nanomed Biotechnol
45:635–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27068140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Aletaha D, Barton A, et al.  (2018). Rheumatoid arthritis. Nat Rev Dis Primers
4:18001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29417936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W, Zhang H, Wang H, et al.  (2017). Targeting notch-activated M1 macrophages attenuates joint tissue damage in a mouse model of inflammatory arthritis. J Bone Miner Res
32:1469–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5489377</ArticleId>
            <ArticleId IdType="pubmed">28256007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang M, Cao X, Zhang K, et al.  (2018). Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression. Cell Death Dis
9:601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5964092</ArticleId>
            <ArticleId IdType="pubmed">29789558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tice RRAgurell E, Anderson D, et al.  (2000). Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing, Environ Mol Mutagen
35(3):206–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10737956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao S, Tang Y, Lv Z, et al.  (2019). Nanomedicine – advantages for their use in rheumatoid arthritis theranostics. J Control Release
316:302–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31715278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Wu G, Wei X, et al.  (2013). Celastrol induced DNA damage, cell cycle arrest, and apoptosis in human rheumatoid fibroblast-like synovial cells. Am J Chin Med
41:615–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23711145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue M, McKelvey K, Shen K, et al.  (2014). Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology
53:2270–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24982240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Ding J, Feng X, et al.  (2017). Scavenger receptor-mediated targeted treatment of collagen-induced arthritis by dextran sulfate-methotrexate prodrug. Theranostics
7:97–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5196888</ArticleId>
            <ArticleId IdType="pubmed">28042319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Feng X, Ding J, et al.  (2017). Nanotherapeutics relieve rheumatoid arthritis. J Control Release
252:108–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28257989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu B, Cheng C, Wu Y, et al.  (2020). Interactions of ferritin with scavenger receptor class A members. J Biol Chem
295:15727–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7667961</ArticleId>
            <ArticleId IdType="pubmed">32907880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yucel Falco C, Falkman P, Risbo J, et al.  (2017). Chitosan-dextran sulfate hydrogels as a potential carrier for probiotics. Carbohydr Polym
172:175–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28606523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Lin X, Zheng R, et al.  (2018). Celastrol alleviates airway hyperresponsiveness and inhibits Th17 responses in obese asthmatic mice. Front Pharmacol
9:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5797758</ArticleId>
            <ArticleId IdType="pubmed">29445341</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
